spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  botulinum toxin Type A 

 HSMN NewsFeed - 1 Nov 2021
Vensica Therapeutics Closes $16 Million Investment Round
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 13 May 2019
AEON Biopharma Appoints BOTOX(R) Therapeutic Head as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jul 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
Biopharmaceuticals Drug Delivery Dermatology Personnel
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jul 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 1 May 2014
BOTOX(R) (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Feb 2014
Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2014
BOTOX(R) (Botulinum toxin type A) Receives Approval in the UK for the Treatment of Ankle Disability due to Lower Limb Spasticity Associated with Stroke in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 9 Oct 2013
ALPHAEON to Launch the First Early Cataract Detection Device
Devices Ophthalmology Licensing Product Launch
 HSMN NewsFeed - 25 Mar 2013
Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 21 Jul 2011
Merz Aesthetics Announces FDA Approval Of XEOMIN(R) (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Jun 2011
Revance Announces $45 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Aug 2010
FDA Approves Merz Pharmaceuticals' Xeomin(R) (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 Jul 2010
BOTOX(R) Receives First Authorisation in UK as Preventative Treatment in Chronic Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jan 2010
Revance Announces Series D Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2009
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 26 Jun 2009
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 Apr 2009
FDA Approves Dysport(TM) for Therapeutic and Aesthetic Uses
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 12 Mar 2009
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 2 Feb 2009
The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 11 Sep 2008
Allergan Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
Revance Announces Series C Expansion
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
 HSMN NewsFeed - 19 Sep 2007
Allergan, Inc. Announces Agreement to Acquire Esprit Pharma, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jul 2007
Mentor Announces Initial Patient Injections in Phase III Study for PurTox(R) Botulinum Toxin Type A
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Jun 2007
Allergan Announces FDA Approval of Label Extensions for JUVEDERM(TM) Ultra and JUVEDERM(TM) Ultra Plus
Devices Dermatology FDA
 HSMN NewsFeed - 17 Jan 2007
Allergan, Inc. Announces Nationwide Availability of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS Dermal Fillers
Devices
 HSMN NewsFeed - 5 Oct 2006
Allergan Integrates Inamed's Commercial and Research and Development Operations within New Corporate Division, Allergan Medical
Devices Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2006
Allergan, Inc. Announces Launch of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 15 May 2006
Mentor Begins U.S. Phase 1 Study of Its Botulinum Toxin Product for Spasmodic Torticollis/Cervical Dystonia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
botulinum toxin Type A
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.